Selective Estrogen Receptor Modulators (SERMs) such as tamoxifen and raloxifene can reduce the occurrence of breast cancer in high risk women by approximately 50%. This presentation will describe the use of a genome-wide association study (GWAS) to identify novel genes associated with breast cancer risk during SERM prevention therapy. Those results were pursued by functional genomic experiments that defined mechanisms responsible for the associations observed during the GWAS. These observations not only moved “beyond biomarkers” to function and underlying mechanism, but they also provided novel insight into mechanisms responsible for individual variation in SERM response phenotypes.

Citation Format: Richard Weinshilboum. SERM breast cancer pharmaco-genomics: Beyond biomarkers. [abstract]. In: Proceedings of the Eleventh Annual AACR International Conference on Frontiers in Cancer Prevention Research; 2012 Oct 16-19; Anaheim, CA. Philadelphia (PA): AACR; Cancer Prev Res 2012;5(11 Suppl):Abstract nr PL04-03.